Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPECT-2 trial of apadenoson versus adenosine for SPECT myocardial perfusion imaging
NL-OMON35903Phase 3Active, not recruiting
- Sponsor
- Forest Research Institute
- Start
- Mar 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronary arteriosclerosis comparing Adenosine then adenosine with Adenosine then apadenoson (2 arms). Primary endpoint: Diagnostic agreement non-inferiority. Started Mar 2012; status: active, not recruiting.
02
Drugs
apadenosonadenosine
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON35903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35903.